Intercept Pharmaceuticals’ attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended.

The drug developer’s INT-787 showed “no clear evidence of potential” in patients with severe alcohol-associated hepatitis …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844